Brief: Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004
07/04/2025 13:53
April 7 (Reuters) - ALX Oncology Holdings Inc ALXO.O: ALX ONCOLOGY RECEIVES IND CLEARANCE FROM U.S. FDA FOR ALX2004, A NOVEL EGFR-TARGETED ANTIBODY-DRUG CONJUGATE ALX ONCOLOGY HOLDINGS INC - TO START PHASE 1 TRIAL FOR ALX2004 IN MID-2025 Source text: ID:nGNX8xgL7D Further company coverage: ALXO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ALX Oncology Holdings
See all newsALX Oncology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview
ALX Oncology Q2 net loss narrows on lower R&D costs
Brief: ALX Oncology Q2 Basic EPS USD -0.13
Brief: Alx Oncology Holdings - Enters Loan And Security Agreement With HSBC Ventures On June 25, 2026 - SEC Filing